Hypertrophic Cardiomyopathy: Diagnosis, Risk Stratification and Treatment

Overview

Journal CMAJ

Date 2012 Oct 31

PMID 23109605

Citations 15

Authors

Daniel L Jacoby

Eugene C Depasquale

William J McKenna

Affiliations

Soon will be listed here.

Citing Articles

Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study.

Masri A, Lester S, Stendahl J, Hegde S, Sehnert A, Balaratnam G J Am Heart Assoc. 2024; 13(8):e030607.

PMID: 38591260 PMC: 11262496. DOI: 10.1161/JAHA.123.030607.

Cardiac Remodeling and Functional Changes in Patients With Hypertrophic Cardiomyopathy: A Longitudinal Observational Study.

Reddy S, Teja D, R R, Vishal L, Gattu H, Nagilla M Cureus. 2023; 15(10):e46610.

PMID: 37936986 PMC: 10626149. DOI: 10.7759/cureus.46610.

Mechanisms of pathogenicity in the hypertrophic cardiomyopathy-associated TPM1 variant S215L.

Halder S, Rynkiewicz M, Creso J, Sewanan L, Howland L, Moore J PNAS Nexus. 2023; 2(3):pgad011.

PMID: 36896133 PMC: 9991458. DOI: 10.1093/pnasnexus/pgad011.

Screening for Hypertrophic Obstructive Cardiomyopathy in Patients With Panic Disorder: A Case Report.

Bonitz T, Scypinski L, Chin J, Lomiguen C Cureus. 2022; 14(11):e31811.

PMID: 36579213 PMC: 9788791. DOI: 10.7759/cureus.31811.

Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.

Bhagwan J, Mosqueira D, Chairez-Cantu K, Mannhardt I, Bodbin S, Bakar M J Mol Cell Cardiol. 2020; 145:43-53.

PMID: 32531470 PMC: 7487780. DOI: 10.1016/j.yjmcc.2020.06.003.

References

Pelliccia A, Fagard R, Bjornstad H, Anastassakis A, Arbustini E, Assanelli D . Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group.... Eur Heart J. 2005; 26(14):1422-45. DOI: 10.1093/eurheartj/ehi325. View

Maron B, Nishimura R, McKenna W, Rakowski H, Josephson M, Kieval R . Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999; 99(22):2927-33. DOI: 10.1161/01.cir.99.22.2927. View

Elliott P, Gimeno J, Tome M, Shah J, Ward D, Thaman R . Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006; 27(16):1933-41. DOI: 10.1093/eurheartj/ehl041. View

Maron B, Savage D, Wolfson J, Epstein S . Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol. 1981; 48(2):252-7. DOI: 10.1016/0002-9149(81)90604-4. View

Elliott P, McKenna W . Hypertrophic cardiomyopathy. Lancet. 2004; 363(9424):1881-91. DOI: 10.1016/S0140-6736(04)16358-7. View

Maron M, Olivotto I, Zenovich A, Link M, Pandian N, Kuvin J . Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006; 114(21):2232-9. DOI: 10.1161/CIRCULATIONAHA.106.644682. View

Monserrat L, Elliott P, Gimeno J, Sharma S, Penas-Lado M, McKenna W . Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003; 42(5):873-9. DOI: 10.1016/s0735-1097(03)00827-1. View

Ralph-Edwards A, Woo A, McCrindle B, Shapero J, Schwartz L, Rakowski H . Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg. 2005; 129(2):351-8. DOI: 10.1016/j.jtcvs.2004.08.047. View

Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C . Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003; 107(17):2227-32. DOI: 10.1161/01.CIR.0000066323.15244.54. View

10.

Fuster V, Ryden L, Cannom D, Crijns H, Curtis A, Ellenbogen K . 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice.... J Am Coll Cardiol. 2011; 57(11):e101-98. DOI: 10.1016/j.jacc.2010.09.013. View

11.

Nishimura R, Trusty J, Hayes D, Ilstrup D, Larson D, Hayes S . Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol. 1997; 29(2):435-41. DOI: 10.1016/s0735-1097(96)00473-1. View

12.

Pelliccia A, Maron B, Spataro A, Proschan M, Spirito P . The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med. 1991; 324(5):295-301. DOI: 10.1056/NEJM199101313240504. View

13.

Topilsky Y, Pereira N, Shah D, Boilson B, Schirger J, Kushwaha S . Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail. 2011; 4(3):266-75. DOI: 10.1161/CIRCHEARTFAILURE.110.959288. View

14.

Sadoul N, Prasad K, Elliott P, Bannerjee S, Frenneaux M, McKenna W . Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997; 96(9):2987-91. DOI: 10.1161/01.cir.96.9.2987. View

15.

Cohn L, Trehan H, Collins Jr J . Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1992; 70(6):657-60. DOI: 10.1016/0002-9149(92)90208-g. View

16.

Elliott P, Gimeno Blanes J, Mahon N, Poloniecki J, McKenna W . Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001; 357(9254):420-4. DOI: 10.1016/S0140-6736(00)04005-8. View

17.

Elliott P, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna W . Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999; 33(6):1596-601. DOI: 10.1016/s0735-1097(99)00056-x. View

18.

Olivotto I, Ommen S, Maron M, Cecchi F, Maron B . Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial?. J Am Coll Cardiol. 2007; 50(9):831-4. DOI: 10.1016/j.jacc.2007.05.018. View

19.

Seggewiss H, Rigopoulos A, Welge D, Ziemssen P, Faber L . Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol. 2007; 96(12):856-63. DOI: 10.1007/s00392-007-0579-8. View

20.

Maron B, Olivotto I, Spirito P, Casey S, BELLONE P, Gohman T . Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000; 102(8):858-64. DOI: 10.1161/01.cir.102.8.858. View